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Ahhouph lipnprutrin change nrter cardiac transplantation have 
been documented. the etTects of tranrplantalion end subsequent 
immunosuppressive therapy lparticularly the combination of 
predniww, azathioprine and cyclmporine) on apolipoprotein 
levels and lipoprotein(a) hare no1 been reported. Fasting cholw 
twoI, triglyccridcs, high density lipoprotein (HDL) cholesterol, 
low density lipapratein (LDI.) cholesterol. apalipoprotein A-l and 
0.100 and lipnprnleints) were exduated in 69conwutive patients 
during the railing period befnorc cardiac transplantation. 
There were 28 dralh, Wore dlrnor organ IdentiAcatlan and 41 
patients rcrekrd a cardiac allograft. The lipopratrln levels of 
lransplant recipients WWE again assayed 3 months @@pew 
tively. Mean (e SEM) ralue~ increased for total plasma choles. 
trrol lfmm I80 * 8 lo 228 * 8 mddl, p s O.WJ), triglycerides 
(fram 126 + 11 lo 207 * Id mg/dk p S O.oOlJ, HDL cholesterol 
(fmom 39 f 2 to 49 * 3 mddl; p C 0.002) and LDL cholesterol 
tfrom 119 + 7 lo 138 I 7 mddk P < 0.02). Awlipoeratein A-l 
and B-100 nlw increased, bu~lip&atein(aj d&eased from Il.7 
f t.7 lo 6.9 f 1.1 mg!dl; p 5 O.OW) afler transplantation. 
Allhnugh lotat cholesterol. triglycerides, LDL cholesterol, 
apolipmiein A-t and B-100 increased dramalically ~lfier cardiac 
transplantation, so did HDL cholesterol, thereby keeping the 
LDLiHDL cholesterol rat10 cdnstant. The surnrklnn dccrelu in 
&oproteinlsI after cardiac tranapbwdation s&ts?hst metab@ 
lism of lipoprotein(n) is independent OF LDL cholesterol and that 
Immunoruppresrive drugs either deccrwse Ihe synlhesis or tn- 
creaSe catahnllsm oi lipopratein(a~. 
(I Am CoU Cardid l!W;lE:926-30) 
Ahhough cardiac Iransplanratian is an accepted rreatmcnt 
for borne patients with end-stage heart failure. the procedure 
still represents a sizable risk in terms of late outcome (II. 
Acute rejection may have decrensed in relative importance, 
but accelerated obstructive vascular disease (sometimes 
referred 10 as chronic rejection) her become a major caw of 
po\t!ransplantation death (2). The prevalence of this prob- 
lem is high: some investigator> (3) estimate that >50% ofall 
palients undergomg cardiac transplantation who survive 23 
years have obrwuctivc vascular disease. Although multiple 
faclors may play a role in this process. one OS the mosl 
imporlant seems IO bc an altered immune environment: 
cla,sii cardiovascular risk factors are possibly less impor- 
tan1 14-6). Although the relative importance of hyperlipi- 
demia in tranrplantation.arsociated atherosclerosis is con- 
troversial, it is not unreasonable to suspect that increased 
blood levels of atherogenic particles will act synergistically 
with immune factors IO accelerate development of coronary 
artery disease (5). 
Previous reports (7-1 I) have documented the presence of 
hygrlipidemia after cardiac transplantation. but alterations 
in various subh-actions of circulating blood lipids afler the 
procedure have not been well studied. Indeed, the effect 
cl card& transplanm~ion on some lipoprotein fractions 
such as lipoprotein(a). a lipoprotein highly correlated with 
coronary artery atherosclerosis. has nol been reported. 
Recent studies (12,131 hove demonstrated the importance of 
lipoprotein(al as a marker for the presence and severiry of 
comoary atherosclerosis in patients not undergoing trans- 
plantation. 
The purpose of this srudy was to prospectively examine 
changers in rotal cholesterol, low density lipoprotein (LDL) 
cholesterol. high density lipoprotein tHDL) cholesterol. 
triglyceridw and particularly apoliproteins A-l. 8-100 and 
lipoprotein (a) in patients undergoing cardiac rransplanta- 
lion. No prospcclive lone~tudinal evaluation ofchanges in all 
of these analytes has yet been reported. 
Methods 
Study subjects. Patients were evaluated m our inslitu- 
tions with the use of protocols previously de&bed I I ). A 
total of 69 paiients were prospectively studied before under- 
going cardiac transplantation. The patients were idenhfied 
with respect to gender. age and origin of congestive hear! 
failure. All patients were included in a serial manner from 
March 1988 to May 1989. A total of 28 patients died before 
receiving a cardiac transplant and were then excluded from 
further data analysis. hledicarion 11s~ were obtained at each 
clinic visit in the posnransplanration period. Lipid ~illues 
were tabulated serially and values obtamed 6 weeks before 
transplantation were compared with those measured 3 
months after transplantation. The mean I +SEM) time inter- 
val between lipid analysis and transplamaGon was 40 * I3 
days: all but one patient had baseline lipid levels measured 
within 5 months of Iransplantation. 
All poaoperariae patients ret eiwd triple-dnrrrp imarrrtro- 
s~rppressiv~ thrwpy with mzhiopritre. ,‘yGsporincz ond 
prednisone. Monoclonal antibody therapy (OKT31 wds not 
used for rejection prophylaxis. but rather for rejection treat- 
ment. Mean daily doses for all palients at 3 monlhs were 
20 mg of prednisone. 7.2 mgikg body weight afcyclosporine 
and 65 mg/day ofazathioprine. None of the patients receivea 
antithymocyte gtobulin. Routine anlibioric therapy was ad- 
ministered in the form of iruravenous cefoxitin or cefurox- 
ime and :his treatmen* was cominued umil removal of chest 
tubes. The average duration of routine antibiolic therapy 
was 72 h. 
Lipid delermlnatiws. Blood samples were obwinrd after 
a 14-h fast. The samples were anticoagulated with ethylene- 
diaminetetraacetic acid (EDTA) aad plasma was separated 
by low speed centrifugagalion. The plasma concenwdliun of 
cholesterol. triglycerides and HDL cholesterol was mea- 
sured according to methods outlined previously 17t. LDL 
cholesterol was calculated by the svandard formula: LDL 
cholesterol = Total cholestcrnl - IlHDL cholesterol - 
TriglyceriderliS) (14). Because triglyceride levels were con- 
sistently +lW mg/dl. this was believed to be an accurate 
extrgolation (14). 
The levels of lipoproteinin) were determined by an cn- 
zyme-linked immunosorberdassay (ELISAl utilizing n 
method previously described (IS). Rabbi15 were immunircd 
with lipoprolein(a) and an anliserum that vas nonr:ecific for 
lipoproteinla) was prepared. The rabbi! an~~hpuprorcinlnl 
serum was adsorbed ui:h human LDL and lhc revdtunl 
LDL anliapolipoprolein B prccipiletc VU* :cmoveJ The 
supernarant yielded n single prccipitin line with lipopro- 
teinlal. but no reaction with LDL on Ouctderlony gclq. 
Pauem samples were qlored at 4OC and analyzed within 48 h. 
Purified lipoproteinla) U’UT i\okued from the plasmi 01 
patients with high levels of tln\ lipoprotein. After mensure- 
ment uf its protein content and immunorcxnvny. this purl- 
fied liplprolein ww used as a primary reference for smn- 
dardiring plasma sampler comaimng lo\\. mcdlum and high 
IipuprotcinW levels. which were then used a~ secondary 
standards. The standard dilution cnrvc uas lincai. with a 
correlntton cneftic~ent of 0.90. Irma- and inlerdssay coeffi- 
clrnls of v&nation were 4% and 9%. respeclively. For 
normnl hpoproleinlal protein lcvcls in rhc range of I 10 
I(1 mg’dl. the contribulion of plarminopen a1 physiotoplc 
concentration 1200 mg/dl) was negligible (161. 
Statistical evaluations. Lipoprotein values were arranged 
according lo pre- and posttransplantation groups and re- 
ported as mean values 5 SEM. The difference bctwecn 
values in each group was analyzed uaug paired I ~csts and 
\tgnificsnce was wiped a1 a p value < 0.05. Linear 
rcgre,sion analysis was ulilizcd to compare changes in 
lipoproteinlal with chanSes in other lipoprotein values. 
informed consent. The sludy protocol was approved by 
the Inuitutlonnl Review Board of Baylor College of Me& 
tine. The Mclhudist Horpitat and St. Luke’s Episcopal 
llosptt.d. All patients gave informed consul before enroll- 
ment in the ,!udy. 
Results 
Rtitw rharacteristia. Of the patients enrered Into rhe 
study. JI underwent cardiac tmnsplardation and were rub- 
scquenlly rcccaluated. There were 34 men (82%) and 7 
Yumen ll7’;1. ranging in age from 23 to 67 year, (mean 2 
SD 5 I I Y.7). The racial distriburion was ?6 white 188%I. 4 
Hispanic Ill%) and I black (2%). The underlying cause of 
conges~e heart failure treated by &msplantation was isch- 
cmia in !Y pilhents (71%). idiopathic in 6 (IJ%). viral in 2 
(59L vatvular III 2 LW). congcn~tal orolher in I each WU. 
Cholealerul levels. Figure I summar~zcs Ihc changes WC 
ohtcrvcd in lofnl, HDL and LDL cholcWxol levels in the 
lranrplnnt rcc~p,en,r. The mean total cholc‘;Ierol level before 
tr;msplan&on was I8D ? 8 mg/dl: after tnnsplanlation. it 
increased to ?ZS ? S mgidl (p c 0.0011. Mean triglycerides 
idw rhan&cd dramillic;rlly 1126 f II m&Ii and 207 5 
I? mgldl. rqxxtively. bcforc and after tranrplantslion: lp c 
O.OOll. HDL cholcstcrul increased from 19 k 2 to 49 t 
3 m&II poatopcrawcly (p < 0.0021 and LDL choiebterol 
ICVEI from 119 i 7 to 13X 5 7 ~ngidl po~topcrativcly lp < 
O.O?L 
Apalipnprolcin levels (Table I). The LDLIHDL choles- 
terol ratio did not change $vtilicamly bccaose both HDL 
and LDL cholcstct-ol ~ncreawl proporlionately. The ratio of 
1.4 bcforc transplantation decreased only slightly after trans- 
planlalion to 3.3 rp > 0.051. The apohpoprotcin A-l lcvcl 
was X6 5 4 m&U1 before transplantation and increased to 
IO5 & 4 mgldl (p < O.lhX) afterward. The apolipoprotrin 
B-IW level wx X3 -’ 4 m&II bcforc transplantaliun. increw 
ing to 101 r 5 ntgIdl (p < O.NMj afterward. The ratio of 
apolipoprotein B-IOOlapolipoprotcin A-l did no1 change. 
Lipaproiein levels. Chanps in IipuprotemW protein lev- 
els were analyzed by several statistical methods. For the 
ent~rc group. the mean lipoproreinial level of 11.7 + 
1.7 mg!di before transplantation (Fig. ?I decreased to 6.8 i 
I.1 mEldI after transplantation (p < 0.001). On furlher 
exammmion. a total of 28 patients had a decrease >I mddl 
fur lipoprotemla) protein after transplantation. The range for 
the decline was I to 22.S mf/dl. A lolal of 13 patienta had 
esxntially no chanpe 1~1 mgidl dccrcax) or an increase: 
o Ave. change = -4.84moldl bu 1 \ ‘p‘o.001 
(range of difference 0 to -0.9 mgldl). The changes in 
lipoprotein(a) were independent of changes in total choles- 
teml. triglycerides. HDL cholcstcrol or LDL cholesterol 
when examined by rcgrekon analysis. 
Discussion 
Changes in lipid and lipoprolein levels after cardiac tww 
plantation. This study confirms and extends earlier obaer- 
vations 17-l 11 that cardiac transplantation cooses significant 
changes in the lipid and lipoprotein profile. There changes 
are multifactorial in origin. All patients in our study had 
severe congestive heart failure with New York Heart .Asso- 
ciation class 111 or IV symptoms before Iransplanlation. 
Many patients had abnormally low cholesterol values before 
t~nsplantation. Thus, correction of heart failure with con- 
comitant correction of hemodynamic abnormalilies and im- 
proved nutritional status may have contributed to the in- 
crease in plasma lipid concentration occurring after 
transplantation. In addition. each patient received immuno- 
suppressive drug therapy consisting of azathioprine. cyclo- 
sporinc and prednisone after transplantation. Several picvi- 
ous studies have cxammed the effects of cyclosporine and 
cortico5teroids on lipids. Cyclosporine raises total choles- 
terol primarily by increasing LDL cholesterol IIf). Cortico- 
steroids. which also raise total cholestercl levels, produce 
this effect primarily by elevating very IP* density lipoprotein 
WLDLI cholesterol and HDL cholesterol 118.19l. Our ob- 
served significant increase in plasma triglycerides retlectr an 
increase in VLDL cholesterol. The increase in apolipopro- 
tein A.1 was accompanied by a paratlel marked increase in 
HDL cholesterol. Alger et al. (20) observed that an increase 
in HDL cholesterol is due primarily to an increase in 
cholesterol within HIlLa. the lipoprotein subfraction lhai 
has the greatest negative: correlation with coronary artery 
disease. 
The posttransplantation elevalion 01 :iDL cholesterol 
was attended by an increase in both LDL cholesterol and the 
major LDL apolipoprotein El-100. Baseline data before 
tmnsplanlalion revealed an LDLiHDL cholesterol re!io of 
3.4. which was WI significantly changed after transplants 
lion. Hence. the relative risk of coronary artery diseav& as 
evaluated by this criterion. was not changed appreciably by 
lransplant&m. Likewise. similar increags were observed 
in mean plasma I:vels of afolipoproteina A-l and B-100. 
such that their mean ratios wcx not si@icantly changed. 
Effect of transplantation on lipnprokin(nl level: role of 
drugs. In striking comra~t to other lipids or apolipoproteins 
measured in this study. the mean level of lipoproteinta) 
protein decreased by >40% durmg the follow-up period aflcr 
,.&ac tranapkmtation. Thiv remarkable decrease m the 
setting of significant increases in LDL cholesterol and apo- 
lipoprotein B-10.3 pruvides =trong s~oport for ihe view that a 
major fraction of lipoprtileintal is metabu:ked through a 
pathway distinctly different from that folly:? by LDL (211. 
Although it rumher of our patients altered their dietary 


